Case Report: Semaglutide-associated depression: a report of two cases
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Semaglutide, as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was approved for glucose control in type 2 diabetes mellitus in 2017 and approved for weight loss in 2021 by the U.S. Food and Drug Administration (FDA). No psychiatric adverse effect associated with semaglutide has been reported so far. Here we report two cases of semaglutide-associated depression. One is a middle-aged man with no previous history of depression who developed depressive symptoms about 1 month after taking semaglutide. The other one is a middle-aged woman with recurrent depressive disorder whose symptoms also recurred about 1 month after semaglutide treatment. Depression was improved or relieved after discontinuation of semaglutide in both cases. Possible psychiatric adverse effects of depression should be taken into consideration when semaglutide is administered to patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“concerns regarding a possible link between semaglutide use and depressive symptoms and suicidal ideation have recently emerged through case reports [91].”
From What Is Food Noise? A Conceptual Model of Food Cue Reactivity (2023) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Epidemiology and determinants of obesity in China
Pan, X.-F., Wang, L., & Pan, A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00045-0 · Cited by 1,554
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · cited 1×
“As a long acting GLP-1 RA, semaglutide can translocate to the brain stem, lateral septum (LS), and hypothalamus, interact directly with various GLP-1 receptor subtypes and modulate the activity of neural pathways involved in food intake, reward, and energy expenditure (19, 20).”
BackgroundGlucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work
Westbrook, A., van den Bosch, R., Määttä, J. I., Hofmans, L., Papadopetraki, D., Cools, R., & Frank, M. J. (2020) · Science · doi:10.1126/science.aaz5891 · Cited by 356
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15677 · Cited by 259 · cited 1×
“Studies in rodents and non-human primates have demonstrated that GLP-1 RAs can lead to a reduction in the intake of alcohol and drugs of abuse (15).”
BackgroundLiu, L., Chen, J., Wang, L., Chen, C., & Chen, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1043789 · Cited by 258
Mietlicki-Baase, E. G., Ortinski, P. I., Rupprecht, L. E., Olivos, D. R., Alhadeff, A. L., Pierce, R. C., & Hayes, M. R. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00413.2013 · Cited by 174
Shu, Y., He, X., Wu, P., Liu, Y., Ding, Y., & Zhang, Q. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.996179 · Cited by 145
O'Neil, P. M., Aroda, V. R., Astrup, A., Kushner, R., Lau, D. C. W., Wadden, T. A., Brett, J., Cancino, A., Wilding, J. P. H., & groups, O. B. O. T. S. A. C. A. –. L. E. I. I. W. A. W. D. (. S. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12963 · Cited by 115 · cited 1×
“However, psychiatric adverse effects, such as suicidal ideation (10), have been reported in studies with other GLP-1 RAs (3, 11).”
ResultMarty, V. N., Farokhnia, M., Munier, J. J., Mulpuri, Y., Leggio, L., & Spigelman, I. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.599646 · Cited by 102
Reddy, I. A., Pino, J. A., Weikop, P., Osses, N., Sørensen, G., Bering, T., Valle, C., Bluett, R. J., Erreger, K., Wortwein, G., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.86 · Cited by 96
Okamoto, A., Yokokawa, H., Nagamine, T., Fukuda, H., Hisaoka, T., & Naito, T. (2021) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00899-9 · Cited by 48
Jensen, M. E., Galli, A., Thomsen, M., Jensen, K. L., Thomsen, G. K., Klausen, M. K., Vilsbøll, T., Christensen, M. B., Holst, J. J., Owens, A., et al. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104772 · Cited by 38
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14500 · Cited by 38
Menzen, M., Berentzen, T. L., Catarig, A.-M., Pieperhoff, S., Simon, J., & Jacob, S. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2007-2061 · Cited by 29 · cited 1×
“There have been also some reports of rare adverse events including hyperglycemia, acute pancreatitis, and acute nephritis (5, 8, 9).”
BackgroundSemaglutide-Associated Acute Interstitial Nephritis: A Case Report
Borkum, M. S., Lau, W., Blanco, P. L., & Farah, M. (2022) · Kidney Medicine · doi:10.1016/j.xkme.2022.100561 · Cited by 16
Bzowyckyj, A. S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13229 · Cited by 14
Cited by
Kornelius, E., Huang, J.-Y., Lo, S.-C., Huang, C.-N., & Yang, Y.-S. (2024) · Scientific Reports · doi:10.1038/s41598-024-75965-2 · Cited by 143
“Li et al. reported two cases of depression associated with the use of semaglutide 19 .”
BackgroundWhat Is Food Noise? A Conceptual Model of Food Cue Reactivity
Hayashi, D., Edwards, C., Emond, J. A., Gilbert-Diamond, D., Butt, M., Rigby, A., & Masterson, T. D. (2023) · Nutrients · doi:10.3390/nu15224809 · Cited by 80
“Additionally, concerns regarding a possible link between semaglutide use and depressive symptoms and suicidal ideation have recently emerged through case reports [91].”
Background
Metadata
- Authors
- Li, J.-R., Cao, J., Wei, J., & Geng, W.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Cao, Jinya
- Wei, Jing
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2023-08-29
- Volume
- 14
- Pages
- 1238353-1238353
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC10495976
- OpenAlex
- W4386246639
- Cited by
- 50
- References
- 22
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 18 · 2023: 2
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Peking Union Medical College Hospital
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- semaglutide, depression, psychiatric adverse effects, GLP-1 receptor agonists, type 2 diabetes, weight loss, recurrent depression, drug discontinuation, antidepressant effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

